Home

Biomarkers

Read time: 4 min

Congress highlights

Psychiatry’s white whale? The search for biomarkers for schizophrenia

Biomarkers are available and used effectively in other disorders– notably some of the cancers...

Read time: 3 min

Marking time: does lack of change raise more questions than answers?

We urgently need markers that reveal people’s risk of developing PD and, if they already have...

Read time: 3 min

Data drives better categorization of patients

Subtypes of Parkinson’s Disease patients with different risks of progression – and...

Read time: 4 min

Neuronal vulnerability, not being neighbors, underlies synuclein spread

Post mortem evidence and connectome mapping show that the distribution of Lewy pathology does not...

Alzheimer's Disease

Read time: 6 min

Advances in the early diagnosis of Alzheimer’s Disease

Many challenges exist in a patient’s journey to their diagnosis of Alzheimer’s Disease...

Read time: 4 min

Schizophrenia – from prodrome to psychosis

Psychosis is preceded by a 3–4 year prodromal phase in 75% of patients, but only 25% of...

Alzheimer's Disease

Read time: 4 min

Unpicking Alzheimer disease and depression

In this symposium four speakers discussed different approaches to investigating the intersection...

Alzheimer's Disease

Read time: 4 min

Biomarkers to enable early diagnosis and intervention and to monitor progression

Clinical diagnosis of Alzheimer’s disease (AD) is difficult and has an error rate of 40%....

Depression, Bipolar

Read time: 3 min

Predicting vulnerability to mood disorders and treatment response

Major depressive disorder (MDD) is ultimately about how the brain responds to the environment, but...

Bipolar, Schizophrenia

Read time: 3 min

Congress highlights

Reconceptualizing psychosis based on biomarker analysis – personalized therapy to prevent disease progression

When an extensive biomarker study characterizing diverse aspects of brain function unexpectedly...

Read time: 4 min

Congress highlights

Mutual benefits: Public–Private Partnerships in CNS Research

Public–Private Partnerships are being developed worldwide to facilitate collaboration between...

Read time: 5 min

Congress highlights

Updating DSM-5 to improve diagnostic validity and reliability and clinical utility

Clinicians and researchers are invited to submit proposals for revisions to the fifth edition of...

Country selection

We are registering that you are located in Brazil - if that's correct then please continue to Progress in Mind Brazil

Not located in Brazil?
Go to a different regional HUB

Continue to Progress in Mind Continue to Progress in Mind Brazil Continue to Progress in Mind Spain Continue to Progress in Mind Italy Continue to Progress in Mind

You are leaving Progress in Mind

Continue to

Cancel

Hello
Please confirm your email

We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.

The information on this site is exclusively intented for health care professionals.

All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.

Accept

Decline

Congress

Register for access to Progress in Mind in your country